Antiphospholipid syndrome: Diagnostic aspects of lupus anticoagulants

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 83-91

  Arnout, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Antiphospholipid antibodies; Antiprothrombin antibodies; Beta 2 glycoprotein I; Lupus anticoagulant

Indexed keywords

BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PROTHROMBIN;

ANALYTIC METHOD; ANTIBODY AFFINITY; ANTIBODY SCREENING; ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CONFERENCE PAPER; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOASSAY; IN VITRO STUDY; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; PROTEIN BINDING; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VEIN THROMBOSIS;

EID: 0034917281     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616204     Document Type: Conference Paper

References (78)

1. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop
2. The natural history of systemic lupus erythematosus: An approach to its study through chronic biologic false-positive reactions
3. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus
4. Acquired inhibitors of blood coagulation
5. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants
6. Hypergammaglobulinaemia, circulating anticoagulant, and biologic false positive Wassermann reaction: A study of 2 cases
7. Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specificity. Mechanism of lupus anticoagulant
8. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure
9. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
10. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic erythematosus (SLE) and in non-SLE disorders
11. The antiphospholipid syndrome: Ten years on
12. Primary antiphospholipid syndrome
13. Lupus anticoagulant and thrombosis - Possible role of inhibition of prostacyclin formation
14. Thromboembolism in patients with the "lupus"-type circulating anticoagulant
15. Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature
16. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases
17. The laboratory heterogeneity of lupus anticoagulants
18. Evaluation of the anticardiolipin antibody test: Report of an international workshop held on April 1986
19. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - A meta-analysis
20. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis
21. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta-2-glycoprotein I (apolipoprotein H)
22. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
23. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
24. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies
25. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I
26. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I
27. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
28. Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity
29. Phospholipid binding plasma proteins required for antiphospholipid antibody detection - An overview
30. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
31. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?
32. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody
33. Role of divalency in the high-affinity binding of anticardiolipin antibody-2-glycoprotein I complexes to lipid membranes
34. Anti-2-glycoprotein I (2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the 2GPI binding to phospholipids
35. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody-beta-2-glycoprotein I complexes on phospholipid surfaces
36. Dimers of beta-2-glycoprotein I mimic the in vitro effects of beta-2-glycoprotein I-anti-beta-2-glycoprotein I antibody complexes
37. Characterization of β2-glycoprotein I binding to phospholipid membranes
38. Beta 2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles
39. Murine monoclonal antibodies against prothrombin with lupus anticoagulant activity: Mechanism of action and reactivity
40. Guidelines for testing and revised criteria for lupus anticoagulants
41. Criteria for the diagnosis of lupus anticoagulants: An update
42. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns
43. The dilute phospholipid APTT: A sensitive assay for verification of lupus anticoagulants
44. Optimisation of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin
45. A clinical study of the lupus anticoagulant
46. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants
47. The Textarin/Ecarin ratio: A confirmatory test for lupus anticoagulants
48. Behavior of diluted activated partial thromboplastin time in pregnant women with a lupus anticoagulant
49. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta-2-glycoprotein I-dependent antiphospholipid antibodies
50. Monoclonal antibodies against beta-2-glycoprotein I: Use as reference material for lupus anticoagulant tests
51. Some murine monoclonal antibodies against human prothrombin have lupus anticoagulant activity
52. Two different incubation times for the activated partial thromboplastin time (APTT): A new criterion for diagnosis of lupus anticoagulant
53. Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity
54. Lupus anticoagulant testing in Europe: An analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I
55. Use of the dilute Russell viper venom time (dRVVT): Its importance and pitfalls
56. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level
57. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile
58. Conceptions and misconceptions in testing for lupus anticoagulants
59. Transient lupus anticoagulants in children: Stepwise disappearance of diagnostic features
60. Time dependency of lupuslike anticoagulants
61. A new lupus anticoagulant neutralization test based on platelet-derived vesicles
62. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure
63. Improved detection of lupus anticoagulants by the dilute Russell's Viper venom time
64. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids
65. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification
66. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin
67. IgG reactivity to phospholipid-bound beta-2-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome
68. Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH
69. Misdiagnosis of LA. Results from a European Concerted Action on Thrombophilia (ECAT) survey using plasma with a spontaneous factor VIII inhibitor
70. Sensitivity of sixteen aPTT reagents for the presence of lupus anticoagulants
71. The sensitivity of different coagulation reagents to the presence of lupus anticoagulant
72. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive aPTT reagent
73. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: Report of 2 cases and review of literature
74. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII
75. Lupus anticoagulants. First French interlaboratory etalanorme survey
76. Clinically important inaccuracies in testing for the lupus anticoagulant: An analysis of results from three surveys of the UK national external quality assessment scheme (NEQAS) for blood coagulation
77. Calibration of the 1st British reference plasma panel for lupus anticoagulants
78. 2GP1 and anti-prothrombin monoclonal antibodies